QOMPAVIST Trademark

Trademark Overview

On Monday, August 29, 2022, a trademark application was filed for QOMPAVIST with the United States Patent and Trademark Office. The USPTO has given the QOMPAVIST trademark a serial number of 97569169. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, June 25, 2024. This trademark is owned by Bayer Aktiengesellschaft. The QOMPAVIST trademark is filed in the Pharmaceutical Products category with the following description:

Contrast media for use in medical imaging
qompavist

General Information

Serial Number97569169
Word MarkQOMPAVIST
Filing DateMonday, August 29, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 30, 2024

Trademark Statements

Goods and ServicesContrast media for use in medical imaging

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 15, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBayer Aktiengesellschaft
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressLeverkusen 51373
DE
Party NameBayer Aktiengesellschaft
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLeverkusen 51373
DE

Trademark Events

Event DateEvent Description
Thursday, September 1, 2022NEW APPLICATION ENTERED
Thursday, September 15, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 14, 2023ASSIGNED TO EXAMINER
Thursday, June 15, 2023NON-FINAL ACTION WRITTEN
Thursday, June 15, 2023NON-FINAL ACTION E-MAILED
Thursday, June 15, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 12, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, September 12, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, November 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 20, 2024ASSIGNED TO LIE
Wednesday, March 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 25, 2024EXAMINERS AMENDMENT -WRITTEN
Monday, March 25, 2024EXAMINERS AMENDMENT E-MAILED
Monday, March 25, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, March 25, 2024EXAMINER'S AMENDMENT ENTERED
Monday, March 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 30, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 6, 2024TEAS DELETE 1(B) BASIS RECEIVED

Related Keywords

qompavist imaging medical media contrast